Anorexia Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Compass Pathways, Pfizer, Amgen, Eli Lilly & Company, Motus Therapeutics, Janssen

Posted on
by

Anorexia Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Compass Pathways, Pfizer, Amgen, Eli Lilly & Company, Motus Therapeutics, Janssen
DelveInsight’s “Anorexia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Anorexia, historical and forecasted epidemiology as well as the Anorexia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

DelveInsight’s “Anorexia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Anorexia, historical and forecasted epidemiology as well as the Anorexia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Anorexia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Anorexia Market Forecast

 

Some of the key facts of the Anorexia Market Report: 

  • The Anorexia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • The lifetime prevalence of anorexia nervosa in adults was 0.6%, according to statistics from the National Institute of Mental Health (NCS-R). Females (0.9%) had a three times greater lifetime prevalence of anorexia nervosa than males (0.3%). With age, prevalence slightly rose
  • Anorexia is not the most frequent eating disorder, despite the fact that it is perhaps the most well-known. Anorexia is less prevalent among adults over 18 than bulimia and binge eating disorder (BED), occurring in less than 0.1% of adults, according to the Centre for Behavioural Health Statistics and Quality
  • Several compounds, including psilocybin, PF-07258669, and others, are in various stages of development and are among the newly discovered medicines
  • Key Anorexia Companies: Compass Pathways, Pfizer, Amgen, Eli Lilly and Company, Motus Therapeutics, Inc., Janssen Pharmaceuticals, Tercica, Bristol-Myers Squibb, Novo Nordisk A/S, and others
  • Key Anorexia Therapies: Psilocybin, PF-07258669, Romosozumab, olanzapine, RM-131, Risperidone, RhIGF-1, Megestrol acetate, SOMATROPINE, and others
  • The Anorexia epidemiology based on gender analyzed that Anorexia is more common in women than in men
  • The Anorexia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Anorexia pipeline products will significantly revolutionize the Anorexia market dynamics.

 

Anorexia Overview

An eating condition called anorexia (AN), formerly known as anorexia nervosa, causes patients to lose more weight than is normal for their age and height. People who have anorexia restrict their caloric intake and the sorts of food they eat. They may also exercise compulsively or purge their meals by purposeful vomiting or improper laxative use.

 

Get a Free sample for the Anorexia Market Report 

https://www.delveinsight.com/report-store/anorexia-market

 

Anorexia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Anorexia Epidemiology Segmentation:

The Anorexia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Anorexia
  • Prevalent Cases of Anorexia by severity
  • Gender-specific Prevalence of Anorexia
  • Diagnosed Cases of Episodic and Chronic Anorexia

 

Download the report to understand which factors are driving Anorexia epidemiology trends @ Anorexia Epidemiology Forecast

 

Anorexia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Anorexia market or expected to get launched during the study period. The analysis covers Anorexia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Anorexia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Anorexia Therapies and Key Companies

  • Psilocybin: Compass Pathways
  • PF-07258669: Pfizer
  • Romosozumab: Amgen
  • olanzapine: Eli Lilly and Company
  • RM-131: Motus Therapeutics, Inc.
  • Risperidone: Janssen Pharmaceuticals
  • RhIGF-1: Tercica
  • Megestrol acetate: Bristol-Myers Squibb
  • SOMATROPINE: Novo Nordisk A/S

 

Discover more about therapies set to grab major Anorexia market share @ Anorexia Treatment Market

 

Scope of the Anorexia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Anorexia Companies: Compass Pathways, Pfizer, Amgen, Eli Lilly and Company, Motus Therapeutics, Inc., Janssen Pharmaceuticals, Tercica, Bristol-Myers Squibb, Novo Nordisk A/S, and others
  • Key Anorexia Therapies: Psilocybin, PF-07258669, Romosozumab, olanzapine, RM-131, Risperidone, RhIGF-1, Megestrol acetate, SOMATROPINE, and others
  • Anorexia Therapeutic Assessment: Anorexia current marketed and Anorexia emerging therapies
  • Anorexia Market Dynamics: Anorexia market drivers and Anorexia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Anorexia Unmet Needs, KOL’s views, Analyst’s views, Anorexia Market Access and Reimbursement 

 

To know more about Anorexia companies working in the treatment market, visit @ Anorexia Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Anorexia Market Report Introduction

2. Executive Summary for Anorexia

3. SWOT analysis of Anorexia

4. Anorexia Patient Share (%) Overview at a Glance

5. Anorexia Market Overview at a Glance

6. Anorexia Disease Background and Overview

7. Anorexia Epidemiology and Patient Population

8. Country-Specific Patient Population of Anorexia 

9. Anorexia Current Treatment and Medical Practices

10. Anorexia Unmet Needs

11. Anorexia Emerging Therapies

12. Anorexia Market Outlook

13. Country-Wise Anorexia Market Analysis (2019–2032)

14. Anorexia Market Access and Reimbursement of Therapies

15. Anorexia Market Drivers

16. Anorexia Market Barriers

17.  Anorexia Appendix

18. Anorexia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services